Kylin Obtains Notice Of Allowance On US Patent For pRNA

Kylin Therapeutics have received a notice of allowance from the US Patent and Trademark Office for its first US patent application. The newly allowed patent, exclusively licensed to Kylin by the Purdue Research Foundation, broadly covers a number of functionalities for Kylin’s lead technology platform – pRNA, or packaging RNA. These include: receptor binding, ribozyme activity and RNA-interference.

The company said that along with its already-granted European counterparts, it believes this seminal patent family will represent rare “new ground” in the field of RNAi and therapeutic RNA. Kylin has several other applications in the pipeline and continues to file in this area.

Following a notice of allowance, the process resulting in final issuance of a patent involves a number of administrative steps that are typically completed in less than a year.

Eric Davis, president and CEO of Kylin, said: “We are excited that the patent office recognises pRNA as an entirely unique platform in this crowded intellectual property space. The pRNA patents are a result of Kylin’s researchers and Guo’s visionary efforts to borrow from nature and create novel, therapeutically-superior RNA molecules. We believe this is an entirely new intellectual property landscape in the field of RNA-based therapeutics, one that is distinct and protectable from other patents in the RNAi and antisense fields.”